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Clozapine,  an ideal  antipsychotic  drug  for the  treatment  of  resistant  schizophrenia,  is con-
sidered  the most  underutilised  treatment  for schizophrenia.  However,  safety  concerns
have  been  raised  about  clozapine-induced  cardiotoxicity,  which  may  lead  to sudden  death,
particularly in  young  patients.  The  exact  mechanism  of  clozapine  cardiotoxicity  has  not
yet been  thoroughly  studied.  This study  aimed  to  investigate  the  possible  mechanisms  of
clozapine-induced  cardiotoxicity  in a  rat  model.  Young  male  Wistar  rats  were  treated  with
clozapine (10, 15  and  25  mg/kg/day,  i.p.)  for  21 days.  Haemodynamic  and  echocardiog-
raphic  studies  were  performed  for  assessment  of  cardiac  functions.  Heart  sections  were
studied  histopathologically  and  immunohistochemically.  Serum  and  cardiac  markers  of
cardiotoxicity,  oxidative  stress,  inﬂammation  and  apoptosis  were  evaluated.  Heart  sec-
tions of CLZ-treated  animals  showed  increased  cardiac  inﬂammation  that  correlated  with
the clozapine  dose.  Serum  levels  of  CK-MB  and  LDH  levels  increased,  as  did  cardiac  levels  of
TNF-, MDA,  NO,  myeloperoxidase  (MPO),  8-OHdG,  caspase-3  and  NF-B  p65.  In contrast,
GSH levels  and  GSH-Px  activity  decreased.  Furthermore,  immunohistochemical  examina-
tion of the  heart  sections  showed  positive  immunostaining  for both  3-nitrotyrosine  and
caspase-3  in all  clozapine-treated  groups.  Clozapine,  particularly  in  relatively  high  doses,
has a clear  cardiotoxic  effect.  This  cardiotoxicity  is  accompanied  by  increased  myocardial
oxidative  stress,  inﬂammatory  cytokines,  DNA  damage  and  apoptosis  with  attenuation  in
antioxidant defences,  thus  explaining  the previously  reported  myocarditis  and pericarditis
during  clozapine  therapy  in clinical  studies.
© 2014  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under
Y-NC-Nthe CC  B
. IntroductionClozapine, a tricyclic dibenzodiazepine, is an atypi-
al antipsychotic drug that is very efﬁcacious in treating
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psychosis, particularly in patients refractory to other
agents [1]. It has a strong antagonistic activity on D4-
dopaminergic receptors [2] serotonergic, noradrenergic
[3], histamine [4] and cholinergic M2  receptors [5]. It differs
from  traditional antipsychotic drugs in that it has relatively
weak  D2-receptor activity and few extrapyramidal side
effects,  and it is effective in treating resistant schizophrenia
[6].Clozapine appears to be particularly beneﬁcial in
patients with schizophrenia who  are suicidal and those
with  substance use disorder [7]. However, some adverse
effects of clozapine have limited its clinical use [8]. A
is is an open access article under the CC BY-NC-ND license
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common and serious adverse effect requiring regular
monitoring is cardiotoxicity [7]. Several cases showing
clozapine-induced myocarditis (including deaths) have
been  reported internationally, 85% of which developed in
the  ﬁrst 2 months of therapy [8]. Most of the patients in
the  reported cases were under 50 years of age. Clinical
studies showed potentially fatal myocarditis, pericarditis,
heart failure and eventually death associated with clozap-
ine  treatment [9].
The  mechanism of clozapine-induced cardiotoxicity is
not  yet clearly understood. Previous studies showed the
presence of cardiac and peripheral blood eosinophilia
associated with clozapine cardiotoxicity, indicating a
possible  IgE-mediated hypersensitivity reaction [10]. In
addition,  clozapine treatment has been associated with
increased levels of the catecholamines, norepinephrine
and epinephrine [11]. Hyper-catecholaminergic states can
signiﬁcantly exacerbate myocarditis in both animals and
patients  [11,12]. Moreover, clozapine-induced myocarditis
has  been associated with an increased release of inﬂamma-
tory  cytokines [13].
Numerous  reports have shown an increase in the level
of  reactive oxygen species (ROS) in the myocardium dur-
ing  the development of myocarditis and heart failure in
experimental animals and in patients [14]. Myocardial
ischaemia can lead to cell injury with the release of ROS
[15].  Cell injury in the ischaemic area also causes inﬁl-
tration of neutrophils, which produce ROS and cytokines.
Certain cytokines, such as tumour necrosis factor- (TNF-
),  trigger mitochondrial release of ROS [16]. In addition,
an  increase in ROS has been detected in various animal
models of heart failure [17,18]. An increase in oxidative
stress, which may  result from increased production of ROS,
a  relative deﬁcit in the endogenous antioxidant defences,
or  both, can cause myocarditis, contractile dysfunction and
cardiomyopathy [17].
Therefore,  this study aimed to investigate the possi-
ble mechanisms of clozapine-induced cardiotoxicity and
the  role of oxidative stress and proinﬂammatory cytokines
in  that process. This study also investigated whether
clozapine-induced cardiotoxicity is associated with cardiac
DNA  damage and possible apoptosis in a rat model.
2. Materials and methods
2.1.  Chemicals
Clozapine (8-chloro-11-(4-methyl-1-piperazinyl)-5H-
dibenzo  [b,e] [1,4] diazepine) (Sigma–Aldrich, Bayouni
Trading Co. Ltd., Al-Khobar, Saudi Arabia) was dissolved in
0.1  M HCl and pH-balanced in phosphate-buffered saline
(PBS)  (Sigma–Aldrich, Bayouni Trading Co. Ltd., Al-Khobar,
Saudi Arabia). This solution was administered intraperi-
toneally (i.p.) daily in 0.1-ml doses. All other chemicals used
in  this study were of analytical grade.
2.2. AnimalsThe animals used in this study were young male Wistar
rats, 3–4 weeks of age and 120–150 g in body weight,
from the animal facility of King Saud University, Riyadh,logy Reports 1 (2014) 1213–1223
Saudi  Arabia. Animals were housed in groups of 10 rats
in  standard clear polycarbonate cages, with food and
water available ad libitum. Animals were kept on a 12-h
light–dark schedule (6:00 am–6:00 pm), and all experi-
mental testing was  conducted during the light phase,
between 9:00 am and 12:00 pm.  All experiments were car-
ried  out in accordance with the National Institutes of Health
guide  for the care and use of laboratory animals (NIH Pub-
lications No. 8023, revised 1978). The Institutional Animal
Use  and Care Committee approved the experimental pro-
tocol.  All efforts were made to minimise animal suffering
and  to reduce the number of animals used.
2.3. Experimental protocol
The  animals were randomly divided into four groups.
Clozapine was administered in doses of 10 (n = 10), 15
(n  = 10) and 25 (n = 13) mg/kg/day i.p. for 21 days in three
groups. The fourth group (n = 10), the control group, was
treated with saline. The moderate to high doses of cloza-
pine  were based on previous reports [12]. The animal’s
body weight (BW) was  measured before and after the study
period.  At the end of the study period (21 days), rats were
anaesthetised with 2% halothane in O2 and subjected to
echocardiographic study followed by haemodynamic mea-
surements. At the end of haemodynamic measurements,
blood samples were drawn by cardiac puncture. Hearts
were excised, washed with ice-cold saline, blotted with a
piece  of ﬁlter paper, and weighed immediately (HW), and
the  ratio to BW (HW/BW) was  calculated. Hearts were then
divided  midventricularly into two halves, with one half
immediately snap-frozen in liquid nitrogen for subsequent
biochemical assays. Ventricles of the second half were used
for  histological and immunohistochemical studies.
2.4. Cardiac function assessments
Left  ventricular (LV) function analysis was performed
via echocardiography and haemodynamic measurement.
Two-dimensional echocardiographic studies were per-
formed  under 0.5% halothane anaesthesia using an
echocardiographic machine equipped with a 7.5-MHz
transducer (SSD-5500; Aloka, Tokyo, Japan). M-mode trac-
ings  were recorded from the epicardial surface of the right
ventricle; the short-axis view of the left ventricle was
recorded to measure the LV dimension in diastole (LVDd)
and  LV dimension in systole (LVDs). LV fractional short-
ening (FS) and ejection fraction (EF) were calculated and
expressed as percentages.
After  the instrumentation, the concentration of
halothane was  reduced to 0.5% to record steady-state
haemodynamic data. Haemodynamic parameters such
as  the mean blood pressure (MBP), peak LV pressure
(LVP), LV end-diastolic pressure (LVEDP), and the rate
of  intraventricular pressure were recorded as previously
described [19].
The  study was  performed in a blinded manner.2.5. Histopathological studies
Slices from ventricles of each heart were ﬁxed in
a  10% neutral formalin solution, then embedded in
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arafﬁn, sectioned at a thickness of 5 m and stained
ith haematoxylin and eosin (H/E), and examined by
ight  microscopy. The ventricle specimens were evalu-
ted  for typical histopathological features associated with
lozapine-induced cardiotoxicity (including inﬂammation,
yocyte vacuolar degradation, necrosis of myoﬁbers, and
nterstitial  ﬁbrosis).
.6.  Biochemical studies
Heart  tissue was homogenised (Biohom homogeniser)
n 20-mM phosphate buffer (pH 7.4) containing 0.5 mM
utylated hydroxytoluene to prevent sample oxidation.
he homogenates were centrifuged at 3000 rpm at 4 ◦C
or  15 min. Serum and the supernatant of the homogenate
ere used for biochemical assays.
.6.1. Determination of CK-MB and LDH activities
Creatinine kinase (CK-MB) activity was estimated in
erum  according to the method of Bishop et al. [20] using
iagnostic kit (Stanbio Laboratory, TX, USA). The increase
n  absorbance at 340 nm is measured spectrophotometri-
ally to calculate CK-MB level as (U/L). LDH activity was
etermined using diagnostic kit provided from Biogamma
Rome, Italy). The increase in absorbance is measured spec-
rophotometrically at 340 nm at 1 min  intervals for 3 min.
erum  total LDH activity was calculated as (U/L) according
o  the method of Whitaker [21].
.6.2. Determination of TNF-˛
TNF- in the cardiac homogenate was assayed using
nzyme-linked immunosorbent assay (ELISA) using a
icroplate reader (Spectra III Classic, Tecan, Salzburg,
ustria) as previously described [22].
.6.3. Determination of lipid peroxidation
Lipid peroxidation was determined in the cardiac
omogenates because thiobarbituric acid reactive species
TBARS; referred to as malondialdehyde, MDA) are con-
idered  markers of oxidative stress. The colour intensity
s  measured spectrophotometrically at 532 nm. Concen-
ration of TBARS was calculated for each sample after
eference to the standard curve.
.6.4. Determination of myocardial total nitrite/nitrate
Nitrate and nitrite are assayed calorimetrically as indi-
ators of NO in the tissue because the half-life of NO is too
hort  and it is proportionately converted into nitrite and
itrate.  Then the total nitrite is then measured by Griess
eaction, according to the method described by Green et al.
23].
.6.5.  Determination of reduced glutathione
Reduced glutathione (GSH) was determined accordingo  the method described before by Beutler et al. [24]. The
rocedure is based on the reduction of 2-nitrobenzoic acid
y  glutathione to produce a yellow compound which was
easured  spectrophotometrically at 405 nm.logy Reports 1 (2014) 1213–1223 1215
2.6.6.  Determination of glutathione peroxidase
Glutathione peroxidase (GSH-Px) activity was  deter-
mined spectrophotometrically by the method of [25].
2.6.7.  Determination of myeloperoxidase activity
Myeloperoxidase (MPO) activity was measured as an
index  of neutrophil accumulation. Tissue MPO  activity was
assessed  using a commercial assay kit (Hycult Biotech Inc.,
Burlington, CA).
2.6.8.  Determination of 8-hydroxy-2-deoxyguanosine
8-OHdG is produced by the oxidative damage of
DNA by reactive oxygen and nitrogen species and serves
as  an established marker of oxidative stress. Cayman’s
8-hydroxy-2′-deoxyguanosine assay kit purchased from
Cayman’s Chemical Co. (USA) was used. It is a com-
petitive assay that can be used for the quantiﬁcation
of 8-OHdG in serum and tissue homogenate. It recog-
nises both free 8-OHdG and DNA-incorporated 8-OHdG.
This  assay depends on the competition between 8-OHdG
and  8-OHdG-acetylcholinesterase (AChE) conjugate (8-
OHdGTracer) for a limited amount of 8-OHdG monoclonal
antibody. All procedures were carried out in accordance
with the manufacturer’s instructions.
2.6.9. Determination of total protein
Total protein concentration was  also determined using
a  bicinchoninic acid (BCA) protein assay kit (Pierce Chem-
icals,  Texas, USA).
2.7.  Western blotting for NF-B p65 cardiac protein
expression
Brieﬂy, 50 g from each sample homogenate was
denatured by boiling for 5 min  in 2% SDS and 5% 2-
mercaptoethanol and loaded into separate lanes of a
12%  SDS-PAGE gel. The samples were separated elec-
trophoretically at 100 V for 2 h. The separated proteins
were electrically transferred onto PVDF membranes using
a  T-77 ECL semi-dry transfer unit (Bioscience, Washing-
ton, USA) for 2 h. The membrane was  blocked in TBS
buffer containing 0.05% Tween and 5% non-fat milk for
one  hour. The membranes were then incubated with either
mouse  monoclonal anti-NF-B p65 or mouse monoclonal
anti-actin (Santa Cruz Biotechnology, Inc.). Polyclonal goat
anti-mouse immunoglobulin conjugated to alkaline phos-
phatase  (Sigma–Aldrich, Chicago, USA) diluted 1:5000 in
the  10×-diluted blocking buffer served as secondary anti-
body.  Protein bands were detected by adding alkaline
phosphatase buffer (100 mM Tris pH 9.5; 100 mM NaCl;
5  mM MgCl2) containing the substrate, 6.6 l NBT/ml and
3.3  l BCIP/ml (from stock of 50 mg/ml  nitro blue tetra-
zolium (NBT) and 50 mg/ml  5-bromo-4-chloro-3-indolyl
phosphate (BCIP) in 70% formamide). Colour reactions were
stopped  by rinsing with stop buffer (10 mM Tris–Cl, pH
6.0,  5 mM EDTA). Relative intensities of protein bands were
analysed  by scanner and quantiﬁed by AIDA Image Ana-
lyzer  software.
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Table  1
Changes in heart weight (HW), body weight (BW) and percent mortality of rats after treatment with clozapine in doses of 10, 15, 25 mg/kg/d for 21 days.
Treatment (mg/kg) n BW (g) HW (g) HW/BW × 10−3 % Mortality
Saline 10 133.6 ± 2.2 1.43 ± 0.06 6.12 ± 0.30 0.0
Clozapine (10) 10 137.4 ± 3.4 1.56 ± 0.04 6.75 ± 0.25 0.0
Clozapine (15) 10 140.4 ± 2.1a 1.63 ± 0.07 a 6.78 ± 0.11a 0.0
Clozapine (25) 13 143.7 ± 2.8a 1.83 ± 0.09b 7.50 ± 0.16b 23.07Results represent mean ± SEM.
a p < 0.05 vs. saline-treated rats.
b p < 0.01 vs. saline-treated rats.
2.8. Immunohistochemistry
In  brief, the sections were de-parafﬁnised in xylene
and rehydrated through graded alcohols, then boiled
in  0.01 M citrate buffer (pH 6.0) for 10 min. Hydrogen
peroxide (0.3%) was added to block any endogenous per-
oxidase  activity. To block nonspeciﬁc binding, the sections
were  incubated with a goat-serum blocking solution com-
posed  of 10% normal goat serum in phosphate-buffered
saline, pH 7.4 and 0.05% sodium azide. The sections were
incubated with anti-caspase-3 (at 1:100 dilution) and anti-
3-nitrotyrosine (at 1:400 dilution) antibodies, respectively,
used at 4 ◦C overnight. Polydetector secondary antibody
was used to avoid contaminating endogenous biotin or
streptavidin (Bio SB, Santa Barbara, CA). After washing,
the antigen–antibody complex was applied and stained
with diaminobenzidine (Bio SB). Counterstaining was per-
formed  lightly with haematoxylin. None-immune serum
was  used instead of the ﬁrst antibody as a negative con-
trol.  All the control slides yielded negative results. One
pathologist, who was unaware of the fate of the tissue
site [26], performed the evaluation of the immunostained
slides.
2.9. Statistical analysis
InStat  version 2.0 (GraphPad Prism 5, ISI Software,
Philadelphia, PA, USA, 1993) was used to compute sta-
tistical  data. All experimental results are expressed as
the  mean ± SEM. Comparisons between experimental and
control  groups were performed by one-way analysis of
variance  (ANOVA) followed by Bonferroni’s test for post
hoc  comparison when appropriate. A value of p < 0.05 was
considered signiﬁcant.
3.  Results
3.1. General toxicity
The  general appearance and BW of animals were
recorded during the time course of the study and HW
at  the end of the study. In the control group and groups
treated with clozapine dose 10 mg/kg there was  no sig-
niﬁcant changes in BW and HW.  The BW,  HW and the
HW/BW ratio were signiﬁcantly increased during the
experiment in groups treated with clozapine at doses
of  15 and 25 mg/kg compared with the control values
(Table 1).3.2.  Effect of clozapine on myocardial functions
Results of changes in haemodynamic and echocardi-
ographic functional parameters are shown in Table 2.
Treatment of animals with clozapine in the tested doses
for  21 days resulted in left ventricular remodelling and sys-
tolic  dysfunction in these animals. These changes appeared
as  increases in LVEDP and LVDS and decreases in LVP, FS
and  EF. These effects were signiﬁcant in moderate to large
doses  (15 and 25 mg/kg) of clozapine.
3.3. Clozapine induced cardiomyopathy
Histopathological studies of cardiac sections of both
control and clozapine-treated animals showed evidence
of  myocarditis and myocardial cellular inﬁltration in car-
diac  sections of clozapine-treated rats compared to control
rats.  These changes took the form of focal subendocardial
ﬁbrosis with marked interstitial oedema and perinuclear
vacuolation. Myocarditis increased with increasing clozap-
ine  doses, with the highest incidence induced by treatment
at  25 mg/kg. Inﬂammatory lesions were found in both
the  left and right ventricles, primarily in the myocardium
below the endocardium of the left ventricle, in the poste-
rior  papillary muscle of the left ventricle and in the septum,
consistent with myocarditis (Fig. 1A–D).
3.4. Effect of clozapine on cardiac biochemical
parameters
3.4.1. Effect on serum CK-MB, LDH levels
Results from measurement of serum CK-MB and LDH
showed signiﬁcant changes in their levels among the tested
groups  [F(3,39) = 7.059, p = 0.0007] and [F(3,39) = 6.517,
p  = 0.0012], respectively. Serum CK-MB signiﬁcantly
increased with the 15 mg/kg dose (p < 0.05) and with the
25  mg/kg dose (p < 0.01) compared with control (Fig. 2A).
In  addition, the serum LDH level signiﬁcantly increased
(p  < 0.05) with the 10-mg/kg dose and (p < 0.01) with the
15  and 25 mg/kg doses of clozapine (Fig. 2B).
3.4.2.  Effect on cardiac MPO  activity and THF-  ˛ level
Cardiac levels of TNF- changed signiﬁcantly after treat-
ment with clozapine [F(3,39) = 6.511, p = 0.0012]. Clozapine
treatment signiﬁcantly increased TNF- level (p < 0.05) at
the  15 mg/kg/d dose and (p < 0.01) at the 25 mg/kg dose
when  compared to control (Fig. 3A). Cardiac MPO  activ-
ity  measurement showed increases in its concentration
in clozapine-treated animals at the signiﬁcance level of
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Table 2
Changes in haemodynamic and echocardiographic functional parameters after 21 days of treatment with clozapine in doses of 10, 15, 25 mg/kg/d in rats.
Functional parameters Control Clozapine (10) Clozapine (15) Clozapine (25)
HR (beat/min) 355 ± 8.3 361 ± 7.6 377 ± 6.6a 386 ± 6.4b
MBP  (mmHg) 94 ± 8.2 96 ± 5.3 93 ± 6.4 98 ± 6.5
LVP  (mmHg) 112 ± 4.0 109 ± 3.3 104 ± 3.4a 94 ± 3.7b
LVEDP (mmHg) 4.52 ± 2.5 6.74 ± 2.4 11.93  ± 2.3a 14.76 ± 3.1a
LVDd (mm) 6.8  ± 1.4 7.3 ± 1.6 7.8  ± 1.5 8.4 ± 1.9
LVDs  (mm) 3.5 ± 0.5 5.5 ± 0.7a 6.2 ± 0.9a 7.5 ± 1.2b
FS (%) 38.5 ± 2.3 28.4 ± 3.3a 26.6 ± 2.6b 19.4 ± 2.8c
EF (%) 72.4 ± 5.5 62.4 ± 7.3 55.6 ± 6.5a 38.8 ± 7.3b
Results are presented as the mean ± SEM (n = 10). HR, heart rate; MBP, mean blood pressure; LVP, left ventricular pressure; LVEDP, left ventricular end-
diastolic  pressure; LVDd, left ventricular dimension in diastole; LVDs, left ventricular dimension in systole; FS, fractional shortening; EF, ejection fraction.
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la p < 0.05.
b p < 0.01.
c p < 0.001 vs control.
 < 0.01 with doses of 10 and 15 mg/kg and at p < 0.001 with
he  dose of 25 mg/kg/d (Fig. 3B).
.4.3. Effect on cardiac oxidative parameters
Results obtained from the effects of clozapine on car-
iac  levels of MDA, NO, GSH and GSH-Px activity are shown
n  Table 3. Clozapine treatment signiﬁcantly affected
yocardial lipid peroxidation and cardiac levels of MDA
F(3,39)  = 7.158, p = 0.0007]. Post hoc analysis indicated that
lozapine  treatment signiﬁcantly increased cardiac MDA
ig. 1. Representative H&E-stained sections (40×) of the left ventricle from saline-
dministration  of saline for 21 days. (B) There are inﬂammatory lesions in the m
here  are larger inﬂammatory lesions in the myocardium after administration of 
esions  in the myocardium after administration of 25 mg/kg/d clozapine for 21 dalevels  at doses of 15 mg/kg (p < 0.05) and 25 mg/kg (p < 0.01)
relative  to control. In addition, regarding myocardial NO
level,  there was a signiﬁcant difference between treated
groups [F(3,39) = 7.374, p = 0.0006]. Clozapine treatment
signiﬁcantly increased cardiac NO levels at doses of
15  mg/kg (p < 0.05) and 25 mg/kg (p < 0.01) relative to con-
trols.
Moreover, clozapine treatment decreased the myocar-
dial GSH level [F(3,39) = 3.512, p = 0.0248], which was
signiﬁcant relative to controls for the 25-mg/kg dose.
 and clozapine-treated rats. (A) There is no myocardial inﬂammation after
yocardium after administration of 10-mg/kg/d clozapine for 21 days. (C)
15-mg/kg/d clozapine for 21 days. (D) There are extensive inﬂammatory
ys.
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Table  3
Effect  of clozapine in doses of 10, 15 and 25 mg/kg/day for 21 days on myocardial malondialdehyde (MDA), total nitrate/nitrite, intracellular reduced
glutathione  (GSH) levels and glutathione peroxidase (GSH-Px) activity in rats.
Treatment (mg/kg/d) MDA  (mol/g protein) Total nitrate/nitrite (mol/g protein) GSH (nmol/g protein) GSH-Px (IU/g protein)
Control 315.62 ± 15.34 3.33 ± 1.14 33.46 ± 3.52 25.45 ± 3.24
Clozapine (10) 332.26 ± 17.25 3.64 ± 2.38 30.45 ± 3.33 18.34 ± 2.48
Clozapine (15) 387.63 ± 13.26a 10.34 ± 1.23a 23.46 ± 3.25 14.67 ± 2.66a
Clozapine (25) 412.52 ± 21.32b 11.24 ± 1.12b 19.85 ± 3.23b 12.45 ± 2.13b
Results in each group represent mean ± SEM (n = 10).
a p < 0.05 vs. control rats.
b p < 0.01 vs. control rats.
Fig. 2. Effect of clozapine treatment in doses of 10, 15 and 25 mg/kg/d, i.p.,
Fig. 3. Effect of clozapine treatment in doses of 10, 15 and 25 mg/kg/d, i.p.,
for  21 days on (A) cardiac levels of tumour necrosis factor alpha (TNF-)
and (B) cardiac myeloperoxidase (MPO) activity in rats. Results in each
to  clozapine treatment. Clozapine-treated rats exhibitedfor  21 days on serum levels of (A) creatinine phosphokinase isoenzyme
(CK-MB) and (B) lactate dehydrogenase (LDH) in rats. Results in each group
represent mean ± SEM (n = 10). *p < 0.05 vs. control. **p < 0.01 vs. control.
Furthermore, clozapine treatment attenuated the GSH-
Px  activity [F(3,39) = 4.586, p = 0.0081], which was signiﬁ-
cant  relative to controls at signiﬁcance level p < 0.05 for the
dose  of 15 mg/kg and p < 0.01 for the dose 25 mg/kg.
3.4.4.  Effect on serum and cardiac 8-OHdG levels
8-Hydroxy-2′-deoxyguanosine (8-OHdG) is a product
of  oxidatively damaged DNA and is formed by hydroxy
radicals and singlet oxygen. Measurement of 8-OHdG lev-
els  revealed signiﬁcant changes among clozapine-treated
groups [F(3,39) = 8.850, p = 0.0002] and [F(3,39) = 6.512,
p  = 0.0012] in serum and cardiac tissues, respectively.
After 21 days of clozapine treatment, the serum 8-OHdG
levels signiﬁcantly increased (p < 0.05) with the dose ofgroup represent mean ± SEM (n = 10). *p < 0.05 vs. control. **p < 0.01 vs.
control. ***p < 0.001 vs. control.
15 mg/kg and more signiﬁcantly increased (p < 0.01) with
the  dose of 25 mg/kg (Fig. 4A). In the hearts, 8-OHdG
levels signiﬁcantly increased (p < 0.05) with the dose
10  mg/kg and more signiﬁcantly (p < 0.01) increased with
the  doses 15 and 25 mg/kg compared to control levels
(Fig. 4B).
3.5.  Effect of CLZ on cardiac NF-B level
We used Western blotting to estimate the level of NF-B
p65  protein that was synthesised by heart cells in responseover-expression of NF-B p65 protein synthesised by the
heart.  This increase was  signiﬁcant at the levels of p < 0.05
with  10 mg/kg, p < 0.01 with 15 mg/kg and p < 0.001 with
25  mg/kg of clozapine (Fig. 5).
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Fig. 4. Effects of clozapine in doses of 10, 15 and 25 mg/kg/d, i.p., for 21
days on the 8-hydroxy-2-deoxyguanosine (8-OHdG) levels in both serum
(A)  and myocardium (B) of normal rats. Results in each group represent
mean ± SEM (n = 10). *p < 0.05 vs. control. **p < 0.01 vs. control.
Fig. 5. Effects of clozapine in doses of 10, 15 and 25 mg/kg/d, i.p., for 21
d
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cal  studies showed that clozapine cardiotoxicity is suddenays on cardiac NF- p65 expression. Results in each group represent
ean ± SEM (n = 10). *p < 0.05 vs. control. **p < 0.01 vs. control. ***p < 0.001
s.  control.
.6. Immunohistochemical detection of 3-nitrotyrosine
nd caspase-3
The control group did not show any immunoreactivity
or 3-nitrotyrosine (Fig. 6A), an indicator of peroxyni-
rite. Administration of clozapine (10, 15, and 25 mg/kg)
ed  to a gradual increase of immunoreactivity of 3-
itrotyrosine, which was evident from the increased
ntensity of the brown staining of cardiac tissues when
ompared to the control group (Fig. 6B–D). The con-
rol group showed little immunoreactivity for caspase-3
Fig. 7A). Clozapine-treated groups at all three dose levels
howed signiﬁcant increases in the numbers of cardiac cellslogy Reports 1 (2014) 1213–1223 1219
showing  immunoreactivity for activated caspase-3 in the
cytoplasm (Fig. 7B–D) compared with the control group.
The  immunohistochemical staining for caspase-3 was
quantiﬁed, and the results are summarised in Fig. 7E.
This  immunohistochemical ﬁnding was conﬁrmed by spec-
trophotometric measurement of caspase-3 activity in
cardiac  tissues. Caspase-3 activity increased in response to
clozapine  treatment at the signiﬁcance level p < 0.05 with
10  mg/kg, p < 0.01 with 15 mg/kg and p < 0.001 with the
dose  25 mg/kg after 21 days of treatment (Fig. 7F).
4.  Discussion
Approximately 30% of individuals diagnosed with
schizophrenia suffer from treatment-resistant or refrac-
tory  schizophrenia. The gold standard for treatment of
refractory schizophrenia is clozapine [8]. However, a sig-
niﬁcant  number of patients cease clozapine therapy. The
main  cause is drug-induced adverse effects, most notably
including myocarditis and cardiomyopathy [7].
The exact mechanisms of clozapine-induced cardiac
toxicity are not yet fully understood. Existing evidence
points to a multitude of molecular mechanisms involved in
clozapine-induced cardiotoxicity. In this study, we investi-
gated  possible mechanisms of clozapine cardiotoxicity and
the  cause of sudden death observed in many patients dur-
ing  the course of clozapine therapy. Because most of the
reported cases of clozapine cardiotoxicity were in young
patients, we performed this study in young (3–4 weeks old)
rats  treated with clozapine for 21 days.
In the present study, all animals treated with clozap-
ine appeared sedated, lethargic and sick for at least 1 h
after  clozapine injection, which may  reﬂect the lethargy
reported in some patients that has been related to clozapine
cardiotoxicity [27]. Clinically, patients receiving clozapine
should be regularly monitored by echocardiography during
treatment; FS and EF are considered the standard indi-
cators of LV function used for diagnosis of cardiotoxicity.
Because clinical cardiac changes were difﬁcult to interpret
by  echocardiography in short-term studies like this one, we
therefore  also measured myocardial functional parameters
(LVEDP) by haemodynamic analysis to further strengthen
our ﬁndings on cardiac changes after clozapine treatment.
Clozapine-treated animals showed dose-related decreases
in  FS and EF but increases in LVEDP, LVDd and LVDs, indi-
cating  LV dysfunction consistent with cardiomyopathy.
Previous studies showed that the potential cardiotoxicity
of clozapine may  be in the form of myocarditis and car-
diomyopathy [28–30].
In  addition, our results showed that treatment with
clozapine in the tested doses induced marked dose-related
inﬂammatory and cardiotoxic effects, with the highest inci-
dence  in response to 25 mg/kg clozapine. Inﬂammatory
lesions were observed in both the left and right ventricles,
mainly in the myocardium below the endocardium of the
left  ventricle, in the posterior papillary muscle of the left
ventricle and in the septum. Although the available clini-and  dose independent, our results showed dose related
cardiotoxic effect of clozapine. Similar results have been
shown  in by Wang et al. [12]. These difference in results
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Fig. 6. Immunohistochemical staining of 3-nitrotyrosine in heart. (A) Section from a control rat showing normal architecture of myocardial tissue and
clozapin
ve stainiabsence  of 3-nitrotyrosine staining. (B–D) Sections from rats treated with 
sive  derangement of myocyte structure and strong 3-nitrotyrosine positi
400×.
of cardiotoxicity between clinical and animal studies may
be  attributed to difference in haemodynamics or the rate
of  formation of clozapine metabolites and free radicals.
The cardiotoxic effects were conﬁrmed by elevation in the
activities  of serum CK-MB and LDH, the two enzymes that
are  considered important markers of early and late cardiac
injury,  especially during clinical follow-up of drug-induced
cardiotoxicities [31].
Among  various hypotheses of clozapine-induced car-
diotoxicity, Killian et al. [7] proposed that clozapine-
induced myocarditis may  result from a type I IgE-mediated
acute hypersensitivity reaction. This hypothesis is sup-
ported  by the onset of clozapine-induced myocarditis,
which commonly includes peripheral eosinophilia and
eosinophilic myocardial inﬁltrates [10]. These reports are
consistent  with our results showing an increase in car-
diac  MPO  level, which is an index of neutrophil migration,
in  clozapine-treated animals. Activated eosinophils induce
tissue  injury and necrosis through the production and
release  of reactive oxygen metabolites and cytotoxic pro-
teins  (e.g., proteases and MPO) into the extracellular ﬂuid
[32].  One possible explanation of this hypothesis comes
from  the fact that clozapine undergoes bioactivation in
myocardial tissue to a chemically reactive nitrinium ion
metabolite, which stimulates cellular injury, lipid perox-
idation and free radical production [33]. These results
are  consistent with our results showing increased car-
diac  levels of the lipid peroxidation product (MDA) withe in doses 10, 15 and 25 mg/kg/d, i.p., for 21 days showing increased mas-
ng with the maximal effect from 25 mg/kg/d of clozapine. Magniﬁcation,
clozapine treatment. This nitrinium ion also binds with
proteins in the myocardium, leading to formation of an
antigenic complex that stimulates the immune response
and  macrophages [34]. This complex subsequently leads to
myocardial  cell damage via the release of free radicals and
the  activation of a variety of proinﬂammatory cytokines
such as TNF- [35]. The increase of cardiac TNF- by cloza-
pine  is dose-dependent [12]. These ﬁndings are consistent
with the results of this study. TNF- is known to be able
to  attract leukocytes to inﬂammatory sites, enhancing the
generation of reactive species [36]. Moreover, TNF- seems
to  be responsible for regulating the production of some
mediators that stimulate inﬂammatory reaction, such as
NF-  and COX-2 [37]. The results of this study clearly
showed an increase in cardiac NF- levels in CLZ-treated
animals.
Previous studies support the concept of the involvement
of TNF- in clozapine-induced cardiotoxicity, in which
clozapine can stimulate in vivo release of TNF- and var-
ious  interleukins [12,13]. In addition, clozapine-induced
myocarditis in humans is accompanied by the release of
proinﬂammatory cytokines, including TNF- [38].
Imbalance in the autonomic system with decreased
parasympathetic tone and increased adrenergic drive has
been  hypothesised to explain the electrophysiological
effects of clozapine, mainly tachycardia at rest. Persis-
tent inappropriate tachycardia has been demonstrated to
induce  an impairment of left ventricular function both
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Fig. 7. The immunohistochemical reaction for activated caspase-3 in heart. (A) Section from a control rat showing few immunostained cardiac muscle
ﬁbres  with caspase-3 staining. (B–D) Sections from rats treated with clozapine in doses of 10, 15 and 25 mg/kg/d, i.p., for 21 days, showing increased positive
immunoreactivity for caspase-3 with the maximal effect from 25 mg/kg/d of clozapine. Magniﬁcation, 400×. (E) Percentage of active caspase-3-positive
cells  in cardiac tissues of clozapine-treated rats. (F) Caspase-3 activity in control and clozapine-treated rats, estimated by ELISA assay. Results in each group
r ***p < 0.
i
a
d
h
c
c
a
t
eepresent  mean ± SEM (n = 10). *p < 0.05 vs. control. **p < 0.01 vs. control. 
n animal models and in humans [39]. Clozapine induces
 rise in plasma catecholamines that correlates with the
egree  of myocardial inﬂammation [40]. Moreover, the
istopathology of clozapine-treated mice showed a signiﬁ-
ant  dose-related increase in myocardial inﬂammation that
orrelated  with plasma catecholamine levels. Propranolol, beta-adrenergic blocking agent, signiﬁcantly attenuated
hese effects [12].
The  clozapine-induced increase in serum levels of cat-
cholamines increases the myocardial oxygen demand,001 vs. control. ****p < 0.0001 vs. control.
both  directly and indirectly via direct myocardial stim-
ulation and increasing cardiac loads [41] in addition
it decreases myocardial oxygen perfusion [42]. More-
over, increased serum level of catecholamines stimulates
renin–angiotensin–aldosterone system leading to fur-
ther  increase in cardiac loads, the fact that explains
the protective role of angiotensin converting enzyme
inhibitors as captopril against clozapine cardiotoxicity [43].
Increased  cardiac loads with decreased perfusion myocar-
dial  ischaemia and increased generation of free reactive
 / Toxico
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oxygen species, leading to increase in myocardial lipid per-
oxidation,  inﬂammation and cell injury. These effects were
reﬂected  in our results in form of increased myocardial
lipid peroxidation product MDA  and 8-OHdG, the marker
of  oxidative DNA damage.
Our  results showed that clozapine signiﬁcantly
increased the cardiac level of nitrites, a stable product
and indirect marker of NO. In addition, the immunohis-
tochemical study showed increased immunoreactivity to
3-nitrotyrosine, the marker of peroxynitrite, in cardiac
tissues of clozapine-treated animals. The myocardial cyto-
toxicity  of peroxynitrite involves direct oxidative injury
to  cardiac cells and damage to proteins, lipids and DNA
[44]  and the nitration of tyrosine residues of pro-apoptotic
proteins in cardiomyocytes [45].
Previous studies showed increases in cardiac NO lev-
els  following exposure to clozapine, an effect that can
be  related to the drug itself or to its metabolite N-
desmethylclozapine via its agonistic activity towards M1
receptors  on cardiac vagal preganglionic ﬁbres [46]. NO
is  an immune regulator and an effector molecule that
mediates tissue injury. Increased formation of NO may
induce negative inotropic effects and become deleteri-
ous to the heart. Where, excess amounts of NO produced
by  inducible nitric oxide synthase (iNOS) appeared to
contribute to the progression of myocardial damage in
myocarditis [47]. Previous studies have demonstrated that
the  cytokines released by the surrounding inﬂammatory
cells were responsible for the induction of iNOS in the cells
of  the cardiovascular system, including the myocytes. TNF-
  can trigger iNOS expression in macrophages and cardiac
myocytes. The overproduction of NO by proinﬂammatory
cytokines may  depress myocyte contractility [48].
Excessive production of ROS and RNS in myocardial
cells leads to the exhaustion of cellular GSH stores and
dysregulation of antioxidant enzymes as GSH-Px, thereby
leading to the impairment of antioxidant defences (Solaini
and  Harris [15]). These effects were reﬂected in our
results in the form of decreases in the GSH level and
GSH-Px activity in cardiac tissues in clozapine-treated
animals. Clinical and experimental investigations sug-
gested  that increased oxidative stress associated with an
impaired  antioxidant defence status initiates a cascade of
reactions  responsible for clozapine-induced cardiotoxicity
[49].
The increase in free radical formation and the atten-
uation of antioxidant defences by clozapine, can lead to
oxidative damage to cellular lipids, proteins and DNA
[44].  This can explain the observed increase in both
serum and cardiac levels of 8-OHdG the biomarker of
DNA  damage and the increase in the expression of NF-B
p65,  the nuclear factor that contributes in inﬂammatory
response and cell apoptosis. Moreover, the results showed
increased expression of caspase-3 in cardiac tissues of
clozapine-treated animals. Caspase-3 is an important
marker of apoptosis, and this ﬁnding indicates that the
clozapine-induced cardiotoxicity can lead to apoptosis
of  cardiac cells. This can be attributed to the observed
increase in oxidative stress with attenuation of antioxidant
defences and the consequent cellular and DNA dam-
age.  Over the long term, these changes can lead to thelogy Reports 1 (2014) 1213–1223
development of myocarditis and cell apoptosis in cardiac
muscle and to profound cardiac injury and cardiomyopathy
[14].
5. Conclusion and recommendations
In  conclusion, clozapine-induced cardiotoxicity is a seri-
ous  and potentially lethal complication during the course
of  clozapine therapy for schizophrenia. Increased myocar-
dial  oxidative stress, inﬂammatory cytokines, cellular and
DNA  damage and apoptosis with attenuation in antioxi-
dant  defences are all contributing factors. This necessitates
a  high degree of clinical care through the course of cloza-
pine  therapy. The use of echocardiographic monitoring as
a  routine periodical check during the course of clozapine
therapy, and biohumoral investigation if any signs of car-
diotoxicity starts to appear is recommended. Interruption
of the clozapine treatment or combination with other drugs
that  can modulate the above-mentioned pathogenesis in
susceptible patients requires further studies.
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